Thursday, November 18, 2021 4:57:50 PM
We were told to expect anything from 1.2 to 1.8 million in revenue (and before some say this is expected by now and has been priced in, you don't price in revenue growth by dropping the share price by 2 thirds).
We were also told we would see vast balance sheet improvements, what this exactly means is a bit more up in the air.
If we are given 1.2 million in revenue, this would means the company is more or less trading at 1.5 times yearly revenue (2.4m yearly, 3.6m mcap at 0.0011), which, even with the debt concerns Bubae talks about, is a completely ridiculous valuation for the stock.
If I extrapolate a bit and go more towards 1.6~1.8 million every 2 quarters or around 3.2, 3.4m yearly, we are currently trading at 1.05 or 1.12 times yearly revenue.
The liabilities are an issue yes, but if Shawn does deliver on his promise, we could very much see ourselves trading at the bare minimum at 4-5 times that projected yearly revenue which could be anywhere from 0.0040 pps to 0.0050 pps, and that would be ignoring that the OTC is fundamentally hype based and sufficient hype could pump this to a less reasonable but maybe achievable penny, provided lenders don't absolutely murder the pump again.
If that will all happen in a glorious couple of weeks or over an entire quarter I can't say as I don't see the future, but I don't see any reason for us to ever touch trips unless someone attempts a hail mary to get themselves some 0.0010 or 0.0009s tomorrow before the earnings on Monday (Shawn honored the 5 day delay this August even if those earnings were disappointing to say the least)
Sorry for the long post, you probably wanted something shorter to read and I turned this in a quasi DD post.
Recent GRST News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 09:45:09 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/22/2023 09:54:23 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/22/2023 09:04:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:55:26 PM
- Form 1-A POS - • Edgar (US Regulatory) • 10/20/2023 07:29:40 PM
- Form 1-A POS - • Edgar (US Regulatory) • 08/29/2023 07:21:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 08:37:36 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 12:43:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/11/2023 04:51:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2023 06:56:41 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM